International expert panel on inflammatory breast cancer: consensus statement for standardized diagnosis and treatment von Dawood, S., Merajver, S.D., Viens, P., Vermeulen, P.B., Swain, S.M., Buchholz, T.A., Dirix, L.Y., Levine, P.H., Lucci, A., Krishnamurthy, S., Robertson, F.M., Woodward, W.A., Yang, W.T., Ueno, N.T., Cristofanilli, M.

Volltext

Does CDKN2A loss predict palbociclib benefit? von Gao, J, Adams, R P, Swain, S M

Volltext

HER2-Neu in Breast Cancer: History and Future Directions von Swain, S.M.

Volltext

Pertuzumab, trastuzumab, and standard anthracycline- and taxane-based chemotherapy for the neoadjuvant treatment of patients with HER2-positive localized breast cancer (BERENICE):... von Swain, S.M., Ewer, M.S., Viale, G., Delaloge, S., Ferrero, J.-M., Verrill, M., Colomer, R., Vieira, C., Werner, T.L., Douthwaite, H., Bradley, D., Waldron-Lynch, M., Kiermaier, A., Eng-Wong, J., Dang, C.

Volltext

Incidence of central nervous system metastases in patients with HER2-positive metastatic breast cancer treated with pertuzumab, trastuzumab, and docetaxel: results from the randomi... von Swain, S.M., Baselga, J., Miles, D., Im, Y.-H., Quah, C., Lee, L.F., Cortés, J.

Volltext

NCCAM/NCI phase 1 study of mistletoe extract and Gemcitabine in patients with advanced solid tumors von Mansky, P.J., Wallerstedt, D.B., Sannes, T., Stagl, J., Johnson, L.L., Blackman, M.R., Grem, J.L., Swain, S.M., Schlodder, D., Monahan, B.P.

Volltext

IMpassion132 double-blind randomised phase III trial of chemotherapy with or without atezolizumab for early relapsing unresectable locally advanced or metastatic triple-negative br... von Dent, R., André, F., Gonçalves, A., Martin, M., Schmid, P., Schütz, F., Kümmel, S., Swain, S.M., Bilici, A., Loirat, D., Villalobos Valencia, R., Im, S.-A., Park, Y.H., De Laurentis, M., Colleoni, M., Guarneri, V., Bianchini, G., Li, H., Kirchmayer Machackova, Z., Mouta, J., Deurloo, R., Gan, X., Fan, M., Mani, A., Swat, A., Cortés, J.

Volltext

138P Anaphylaxis and hypersensitivity in trials of intravenous pertuzumab + trastuzumab (PH IV) or the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injecti... von Swain, S.M., Tan, A., Gianni, L., Kümmel, S., Dang, C., Schneeweiss, A., O'Shaughnessy, J., Liu, H., Aguila, C., Heeson, S., Macharia, H., Restuccia, E., Loibl, S.

Volltext

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab von Swain, S.M., Schneeweiss, A., Gianni, L., Gao, J.J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M.S., Yoo, B., Cortes, J., Baselga, J.

Volltext

Health-related quality-of-life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer von Cortés, J., Baselga, J., Im, Y.-H., Im, S.-A., Pivot, X., Ross, G., Clark, E., Knott, A., Swain, S.M.

Volltext

Tall tales from sly dwarves: novel functions of gibberellins in plant development von Swain, Stephen M., Singh, Davinder P.

Volltext

43O Pertuzumab/trastuzumab in early stage HER2-positive breast cancer: 5-year and final analysis of the BERENICE trial von Dang, C., Ewer, M.S., Delaloge, S., Ferrero, J-M., Colomer, R., de la Cruz Merino, L., Dadswell, K., Verrill, M., Eiger, D., Sarkar, S., de Haas, S., Restuccia, E., Swain, S.M.

Volltext

Effect of docetaxel duration on clinical outcomes: exploratory analysis of CLEOPATRA, a phase III randomized controlled trial von Miles, D., Im, Y.-H., Fung, A., Yoo, B., Knott, A., Heeson, S., Beattie, M.S., Swain, S.M.

Volltext

Correction to: Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab von Swain, S.M., Schneeweiss, A., Gianni, L., Gao, J.J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M.S., Yoo, B., Cortes, J., Baselga, J.

Volltext

42O Biomarker analysis from KAITLIN, a randomised phase III study of adjuvant trastuzumab emtansine (TDM-1; K) plus pertuzumab (P) versus trastuzumab (H) plus taxane (T) plus P aft... von Metzger, O., Lambertini, C., Krop, I.E., Lewis Phillips, G., Perou, C.M., Symmans, F., Melero, I., Harbeck, N., Winer, E.P., Im, S-A., Barrios, C.H., Bonnefoi, H., Gralow, J.R., Ellis, P.A., Gianni, L., Toi, M., Swain, S.M., Boulet, T., Song, C., de Haas, S.

Volltext

Incidence and management of diarrhea in patients with HER2-positive breast cancer treated with pertuzumab von Swain, S.M., Schneeweiss, A., Gianni, L., Gao, J.J., Stein, A., Waldron-Lynch, M., Heeson, S., Beattie, M.S., Yoo, B., Cortes, J., Baselga, J.

Volltext

Quantitative Evaluation of Fiber from Nonforage Sources Used to Replace Alfalfa Silage von Swain, S.M., Armentano, L.E.

Volltext

First-line treatment patterns by age for patients (pts) with HER2+ metastatic breast cancer (MBC) in the SystHERs registry von Jahanzeb, M., Tripathy, D., Hurvitz, S.A., O'Shaughnessy, J., Mason, G., Yardley, D.A., Brufsky, A., Rugo, H.S., Cobleigh, M., Swain, S.M., Chu, L., Antao, V., Yoo, B., Kaufman, P.A.

Volltext

Baseline characteristics and first-line (1L) treatment of patients with HER2+ metastatic breast cancer (MBC) from the SystHERs registry von Kaufman, P.A., Hurvitz, S.A., O'Shaughnessy, J., Mason, G., Yardley, D.A., Brufsky, A., Rugo, H.S., Cobleigh, M., Swain, S.M., Tripathy, D., Chu, L., Antao, V., Yoo, B., Jahanzeb, M.

Volltext

Patient-reported outcomes predict survival and adverse events following anticancer treatment initiation in advanced HER2-positive breast cancer von Modi, N.D., Danell, N.O., Perry, R.N.A., Abuhelwa, A.Y., Rathod, A., Badaoui, S., McKinnon, R.A., Haseloff, M., Shahnam, A., Swain, S.M., Welslau, M., Sorich, M.J., Hopkins, A.M.

Volltext